46
Participants
Start Date
August 22, 2017
Primary Completion Date
December 12, 2019
Study Completion Date
February 10, 2022
Pembrolizumab
Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
Paclitaxel
"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
Carboplatin
"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
University of Iowa Hospitals and Clinics, Iowa City
University of Minnesota, Minneapolis
Northwestern Medicine Lake Forest Hospital, Lake Forest
Northwestern University, Robert H. Lurie Cancer Center, Chicago
Ironwood Cancer and Research Centers, Mesa
Collaborators (1)
Merck Sharp & Dohme LLC
INDUSTRY
Hoosier Cancer Research Network
OTHER
Daniela Matei, MD
OTHER